#### 1 Integration of single cell omics with biobank data discovers *trans* effects

### of *SREBF1* abdominal obesity risk variants on adipocyte expression of more than 100 genes

- 3 4
- 5 Mihir G. Sukhatme<sup>1</sup>, Asha Kar<sup>1,2</sup>, Uma Thanigai Arasu<sup>3</sup>, Seung Hyuk T. Lee<sup>1</sup>, Marcus Alvarez<sup>1</sup>,
- 6 Kristina M. Garske<sup>1</sup>, Kyla Z. Gelev<sup>1</sup>, Sandhya Rajkumar<sup>1</sup>, Sankha Subhra Das<sup>1</sup>, Dorota
- 7 Kaminska<sup>4,5</sup>, Ville Männistö<sup>6,7</sup>, Hilkka Peltoniemi<sup>8</sup>, Sini Heinonen<sup>9</sup>, Ulla Säiläkivi<sup>10</sup>, Tuure
- 8 Saarinen<sup>10</sup>, Anne Juuti<sup>10</sup>, Kirsi H. Pietiläinen<sup>9,11</sup>, Jussi Pihlajamäki<sup>4,12</sup>, Minna U. Kaikkonen<sup>3</sup>,
- 9 Päivi Pajukanta<sup>1,2,13,\*</sup>
- 10
- 11
- <sup>1</sup>Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA
   <sup>2</sup>Bioinformatics Interdepartmental Program, UCLA, Los Angeles, CA, USA
- <sup>3</sup>A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
- <sup>4</sup>Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
- <sup>5</sup>Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA,
- 17 Los Angeles, CA, USA
- 18 <sup>6</sup>Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio,
- 19 Finland
- 20 <sup>7</sup>Department of Internal Medicine, Kuopio University Hospital, Kuopio, Finland
- 21 <sup>8</sup>Eira Hospital, Helsinki, Finland
- <sup>9</sup>Obesity Research Unit, Research Program for Clinical and Molecular Metabolism, Faculty of
- 23 Medicine, University of Helsinki, Helsinki, Finland
- 24 <sup>10</sup>Department of Abdominal Surgery, Abdominal Center, Helsinki University Hospital and
- 25 University of Helsinki, Helsinki, Finland
- 26 <sup>11</sup>HealthyWeightHub, Endocrinology, Abdominal Center, Helsinki University Central Hospital
- 27 and University of Helsinki, Helsinki, Finland
- 28 <sup>12</sup>Department of Medicine, Endocrinology and Clinical Nutrition, Kuopio University Hospital,
- 29 Kuopio, Finland
- <sup>13</sup>Institute for Precision Health, David Geffen School of Medicine at UCLA, Los Angeles, CA,
   USA
- 32 \*Corresponding author ppajukanta@mednet.ucla.edu

- 34
- 35
- 36
- 37
- 38
- 39

40

#### 41 Abstract

Given the fast-increasing prevalence of obesity and its comorbidities, it would be critical to 42 43 improve our understanding of the cell-type level differences between the two key human adipose 44 tissue depots, subcutaneous (SAT) and visceral adipose tissue (VAT), in their depot-specific 45 contributions to cardiometabolic health. We integrated cell-type level RNA- and ATAC-seq data 46 from human SAT and VAT biopsies and cell-lines to comprehensively elucidate transcriptomic, 47 epigenetic, and genetic differences between the two fat depots. We identify cell-type marker 48 genes for tissue specificity and functional enrichment, and show through genome-wide 49 association study (GWAS) and partitioned polygenic risk score (PRS) enrichment analyses that 50 the marker genes upregulated in SAT adipocytes have more prominent roles in abdominal 51 obesity than those of VAT. We also identify *SREBF1*, a master transcription factor (TF) of fatty 52 acid synthesis and adipogenesis, as specifically upregulated in SAT adipocytes and present in 53 numerous SAT functional pathways. By integrating multi-omics data from an independent 54 human cohort, we further show that the risk allele carrier status of seven abdominal obesity 55 GWAS variants in the *cis* region of *SREBF1* affects the adipocyte expression of 146 SAT 56 adjocyte marker genes in *trans*. We replicate this finding independently in the UK Biobank by 57 showing that the partitioned abdominal obesity PRSs of the *trans* gene sets differ by the regional 58 SREBF1 risk allele carrier status. In summary, we discover the master TF, SREBF1, driving the 59 SAT adipocyte expression profiles of more than a hundred of adipocyte marker genes in trans, a 60 finding that indicates that human *trans* genes can be identified by integrating single cell omics 61 with biobank data.

62

#### 63

#### 64 Abbreviations

- 65 ASPC Adipose stem and progenitor cell
- 66 ATAC Assay for transposase accessible chromatin
- $67 \quad AUC Area under the curve$
- 68 BMI Body mass index
- 69 CCA Canonical correlation analysis
- 70 CMD Cardiometabolic disease
- 71 DE Differential expression
- 72 DA Differential accessibility
- 73 GWAS Genome-wide association study
- 74 KOBS Kuopio Obesity Surgery Study
- 75 LD Linkage disequilibrium
- 76 LEC Lymphatic endothelial cells
- 77 MASLD Metabolic dysfunction-associated steatotic liver disease
- 78 MGSBT Marker genes shared between the SAT and VAT tissues
- 79 MGSS Marker genes specific to SAT
- 80 MGSV Marker genes specific to VAT
- 81 NK Natural killer cells
- 82 PCA Principal component analysis
- 83 PRS Polygenic risk score
- 84 RNA-seq RNA-sequencing
- 85 RYSA Roux-en-Y Gastric Bypass versus Single-Anastomosis Gastric Bypass

- 86 SAT Subcutaneous adipose tissue
- 87 SMC Smooth muscle cells
- 88 snRNA-seq Single nucleus RNA-sequencing
- 89 SREBF1 Sterol regulatory element-binding transcription factor 1
- 90 T2D Type 2 diabetes
- 91 TF Transcription factor
- 92 UKB UK Biobank
- 93 VAT Visceral adipose tissue
- 94 WHRadjBMI Waist-hip ratio adjusted for BMI

95

#### 97 Introduction

Subcutaneous (SAT) and visceral adipose tissue (VAT) are the two key fat depots in humans. 98 99 SAT has many important functional roles, including lipogenesis, lipolysis, hormonal, and 100 endocrine functions, and SAT is also the fat depot that expands most in the presence of 101 obesity<sup>1,2</sup>. Efficient adipogenesis (i.e. differentiation of preadipocytes to adipocytes) is critical 102 for this expansion and buffering against lipotoxicity and low-grade inflammation, the hallmark 103 of obesity<sup>1,3</sup>. VAT, i.e. the deeper intra-abdominal fat that lines internal organs, has a lesser 104 capacity to expand in the presence of obesity and is even more prone to pro-inflammatory profiles than SAT<sup>1,4,5</sup>. It has been postulated that efficient SAT adipogenesis is likely relevant for 105 106 this VAT inflammation as well<sup>6</sup>; however, the actual tissue- and cell-type-specific functions of 107 VAT are not comprehensively understood in humans<sup>4</sup>, likely partly reflecting the practical 108 difficulties in obtaining human VAT samples. Thus, it would be crucial to advance our 109 understanding of the cell-type level transcriptional differences between these two human main 110 fat depots and how they relate to depot-specific contributions to cardiometabolic health and 111 disease.

112

Previous bulk tissue RNA-seq studies have successfully identified *cis* regulatory variants and
their targets genes in local *cis* expression quantitative trait locus (*cis*-eQTL) analyses<sup>7–10</sup>
Furthermore, SAT bulk tissue analysis have detected abdominal obesity associated coexpression networks, regulated by transcription factors (TFs), such as *TBX15*<sup>11</sup>, suggesting
that TFs regulate cardiometabolic trait -associated gene expression in fat depots in *trans*.
However, identification of *trans* regulatory variants and their target genes has been
challenging in SAT and VAT due to the extensive multiple testing issue of the *trans*-eQTL

120	analysis and small samples sizes of SAT and VAT data available for study, which has
121	hampered powerful enough trans-eQTL discovery. Accordingly, very few trans signals have
122	been identified <sup>12,13</sup> and replicated in SAT or VAT. Thus, it is not well understood how variant
123	level differences in TFs, especially in disease-connected GWAS effect alleles, contribute to
124	downstream target genes in trans in bulk tissues, and even less is known about single cell level
125	trans regulatory variants their target genes in SAT or VAT.

126

127 To advance *trans* gene discovery, we first performed dual-tissue single nucleus RNA-sequencing 128 (snRNA-seq) from the same individuals' SAT and VAT biopsies, which identified the unique 129 cell-type marker genes in each fat depot for the main cell-types between SAT and VAT. We then 130 separated these markers into those specific to SAT, specific to VAT, and shared between the two 131 tissues. This design helped us identify a key adipose tissue TF, Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1)<sup>14,15</sup>, among the unique SAT marker genes, present in 132 133 87% of functional pathways of SAT adipocytes, suggesting that it exhibits an important *trans* 134 regulatory role. Next, we found regional abdominal obesity -associated GWAS variants landing 135 in SAT adjpocyte open chromatin in the *cis* region of *SREBF1*. Using a large set of SAT snRNA-136 seq data from an independent human cohort, we then identify more than one hundred SREBF1 137 target genes, the adipocyte expression of which differ by the SREBF1 abdominal obesity GWAS 138 risk variant carrier status. Finally, we discover by building regional PRSs for the SREBF1 trans 139 target genes in the independent UK Biobank, that their abdominal obesity PRSs differ by the risk 140 allele carrier status of the SREBF1 abdominal obesity GWAS variants, providing thus 141 converging evidence to the single cell level data about the trans effects of this key TF. Overall,

- 142 our study integrate single cell omics and biobank data to identify a master SAT TF and a large
- 143 number of its *trans* regulated adipocyte genes for abdominal obesity.

144

#### 146 Methods

#### 147 Study cohorts

- 148 KOBS cohort
- 149 In our dual tissue study design, we analyzed both subcutaneous (SAT) and visceral adipose
- 150 tissue (VAT) single nucleus RNA-sequencing (snRNA-seq) data from matching seven Finns
- 151 with obesity (2 females and 5 males) from the Kuopio Obesity Surgery Study (KOBS)
- 152 cohort<sup>16,17</sup>. This cohort comprises individuals with severe obesity (BMI>30 kg/m<sup>2</sup>) who
- 153 underwent bariatric surgery, and whose SAT and VAT biopsies were both collected at the
- surgery baseline for these single-cell level omics analyses. The mean BMI and age of these seven
- individuals are 38.03 kg/m<sup>2</sup> (SD=1.76) and 54.11 years (SD=2.03). All participants provided
- 156 informed written consent. The study was approved by the local ethics committee. All research

157 conformed to the principles of the Helsinki Declaration.

158

#### 159 UKB cohort

160 For our genome-wide association study (GWAS) enrichment, polygenic risk score (PRS), and partitioned heritability analysis, we used the UK Biobank (UKB)<sup>18</sup>. Given that our single-cell 161 162 level data are of European origin, we only included the unrelated European-origin UKB participants (n=391,701) in our analysis. As described previously<sup>18,19</sup>, the genotype data for these 163 164 individuals were generated using two highly overlapping genotype arrays, Applied Biosystems 165 UK BiLEVE Axiom Array (807,411 markers) and Applied Biosystems UK Biobank Axiom Array (825,927 markers)<sup>18</sup>, and imputed using the Haplotype Reference Consortium (HRC), 166 UK10K, and 1000 Genomes panels<sup>19</sup>. Data from UKB were accessed under application 33934. 167 168

#### **RYSA cohort**

170	Finnish individuals with obesity were recruited for the RYSA bariatric surgery study at the
171	Helsinki University Hospital, Helsinki, Finland, as described previously <sup>20</sup> . In this study, we used
172	the operation time-point SAT snRNA-seq data from 68 RYSA participants with obesity to test
173	whether adipocyte expression of SAT adipocyte marker genes is affected in <i>trans</i> by the risk
174	allele carrier status of seven WHRadjBMI GWAS variants in the SREBF1 cis region. The RYSA
175	study was approved by the Helsinki University Hospital Ethics Committee, and all participants
176	provided a written informed consent. All research conformed to the principles of the Helsinki
177	Declaration.
178	
179	Genotype quality control and imputation in the KOBS and RYSA cohorts
180	We genotyped DNAs of KOBS participants using the Infinium Global Screening Array-24 v1
181	(Illumina). We performed quality control (QC) on the genotype data using PLINK v1.9 <sup>21</sup> by
182	excluding individuals with missingness >2% and removing unmapped, strand ambiguous, and
183	monomorphic SNPs in addition to variants with missingness >2% and Hardy-Weinberg
184	Equilibrium (HWE) <i>p</i> -value<10 <sup>-6</sup> . We further imputed biological sex using the 'sex-check'
185	function in PLINK v1.9 <sup>21</sup> and cross-checked with the reported sex of each individual.
186	
187	We performed genotype imputation against the HRC reference panel version r1.1 2016 <sup>22</sup> on the
188	Michigan imputation server after removing duplicate variants and variants with allele mismatch
189	with the reference panel. Strand flips or allele switches needed to match the reference panel were
190	performed on the server before haplotype phasing using Eagle v2.4 <sup>23</sup> and genotype imputation

191	using minimac4 <sup>24</sup> . We performed QC on the imputed genotype data by removing SNPs with
192	imputation score $R^2 < 0.3$ and HWE <i>p</i> -value $< 10^{-6}$ for the downstream analyses.
193	
194	We genotyped the RYSA participants' DNAs using the Infinium Global Screening Array-24 v1
195	(Illumina). Genotype data QC, imputation, and post-imputation QC were performed for the
196	RYSA cohort as described above.
197	
198	Nuclei isolation in VAT biopsies from the KOBS cohort
199	To isolate nuclei from the snap-frozen VAT biopsies from the KOBS participants, we first
200	combined and minced the VAT samples in a petri dish over dry ice and immediately transferred
201	the minced tissue into a 500 $\mu l$ chilled 0.1X Lysis Buffer consisting of 10 mM Tris-HCl, 10 mM
202	NaCl, 3 mM MgCl <sub>2</sub> , 0.1% Tween-20, 0.1% IGEPAL CA-630, 0.01% Digitonin, 1% BSA, 1 mM
203	DTT, and 1 U/ $\mu$ L RNase inhibitor. After a 15-minute incubation period, the lysate mixed with a
204	500 µl chilled Wash Buffer containing 10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl <sub>2</sub> , 1% BSA,
205	0.1% Tween-20, 1 mM DTT, and 1 U/ $\mu$ L RNase inhibitor was passed through a 70 $\mu$ m Flowimi
206	Cell Strainer into a 2 ml tube. Nuclei were centrifuged at 500 rcf for 5 minutes at 4°C and the
207	supernatant was removed without disrupting the nuclei pellet, followed by a resuspension in a 1
208	ml chilled Wash Buffer. Nuclei were passed through a 40 $\mu$ m Flowimi Cell Strainer into a 2 ml
209	tube and centrifuged at 500 rcf for 5 minutes at 4°C. We removed the supernatant without
210	disrupting the nuclei pellet and resuspended in a 30 $\mu$ l chilled Diluted Nuclei Buffer containing
211	1X Nuclei Buffer (10x Genomics), 1 mM DTT, and 1 U/ $\mu$ l RNase inhibitor. We measured the
212	concentration and overall quality of the nuclei using Countess II FL Automated Cell Counter
213	after staining with trypan and DAPI and used the Single Cell Multiome ATAC + Gene

214	Expression Reagent Kit (10x Genomics) for the joint snRNA- and snATAC-seq library
215	construction. We analyzed the quality of cDNA and libraries using Agilent Bioanalyzer and
216	sequenced the libraries on an Illumina NovaSeq X Plus (snRNA) and Next seq 500 (snATAC)
217	with a target sequencing depth of 400 million read pairs for both snRNA- and snATAC-seq.
218	
219	Nuclei isolation in SAT biopsies of the KOBS and RYSA cohorts
220	We performed SAT snRNA-seq experiments on the snap-frozen SAT biopsies from the KOBS
221	participants, as previously described <sup>11</sup> . Briefly, we first pooled approximately 100 mg of each
222	biopsy and isolated nuclei from the pooled biopsies as described earlier <sup>11</sup> . Next, we measured the
223	concentration and overall quality of the nuclei using Countess II FL Automated Cell Counter
224	after staining with trypan and DAPI and used the Single Cell 3' Reagent Kit v3.1 (10x
225	Genomics) for the library construction. We analyzed the quality of cDNA and gene expression
226	library using Agilent Bioanalyzer and sequenced the library on an Illumina NovaSeq SP with a
227	target sequencing depth of 600 million read pairs.
228	
229	In this study, we used the operation time-point SAT snRNA-seq data from 68 participants with
230	obesity of the RYSA cohort, generated as part of the full RYSA cohort, by randomly pooling 8
231	SAT samples/batch for nuclei isolation. We isolated nuclei and constructed libraries for SAT
232	snRNA-seq from each batch as described above and sequenced libraries from all batches
233	together on an Illumina NovaSeq S4 with a target sequencing depth of 400 million read pairs per
234	batch.
235	
236	Processing of the SAT snRNA-seq data from the RYSA cohort

237 We aligned the raw snRNA-seq data in a FASTQ format file for each batch against the GRCh38 human genome reference and GENCODE v42 annotations<sup>25</sup> using STAR v2.7.10b<sup>26</sup> with the '--238 soloFeatures GeneFull' option to account for full pre-mRNA transcripts. We evaluated the 239 quality of the raw and mapped snRNA-seq data using FastQC. Next, we used DIEM v2.4.0<sup>27</sup> to 240 241 remove empty droplets and droplets with high amounts of ambient RNA. We set droplets with 242 UMI $\leq$ 500 as debris, used k=50 for the initialization step with k-means clustering, and otherwise 243 used the default parameters. After the clustering step, we removed clusters of highly 244 contaminated droplets characterized by low average UMIs, low average number of unique genes 245 detected (nFeatures), high percentage of reads mapped to the mitochondrial genome (%mito), 246 and high number of mitochondrial and ribosomal genes as top expressed features. Next, we used Seurat v4.3.0.1<sup>28</sup> to remove low-quality droplets with UMI<500, nFeatures<200, %mito>10%, 247 248 and spliced read fraction 275%, log-normalize gene counts using the 'NormalizeData' function, 249 identify top 2,000 variable genes excluding mitochondrial and ribosomal genes using the 250 'FindVariableFeatures' function, scale the normalized gene counts to mean 0 and variance 1 251 using the 'ScaleData' function, perform principal component analysis (PCA) using the 252 'RunPCA' function, and cluster the nuclei with a standard Louvain algorithm, first 30 PCs, and a 253 resolution of 0.5. For the remaining nuclei, we removed contaminated counts using DecontX<sup>29</sup> 254 with the previously removed low-quality nuclei as the background and the Seurat cluster 255 assignment as the 'z' and removed additional low-quality nuclei with UMI<500, UMI>30,000, 256 nFeatures<200, and %mito>10% based on the remaining clean counts. To identify the 257 originating participant of each nucleus, we used demuxlet from popscle software tool<sup>30</sup> with '--258 min-MQ 30' and high-quality imputed genotype data. We only included nuclei classified as a 259 singlet and assigned the best matching participant to identify the originating participant for each

nucleus. Next, we used DoubletFinder<sup>31</sup> to identify and remove any remaining doublets. As
DoubletFinder requires predicted number of doublets in each dataset, we performed pN-pK
parameter sweeps on a subset of 10,000 nuclei to select pN of 0.25 and the most optimal pK
value maximizing mean-variance normalized bimodality coefficient for each batch, as previously
recommended<sup>27</sup>.

265

After performing the QC, we used Seurat  $v4.3.0.1^{28}$  to merge all remaining high-quality droplets 266 267 from the batches and subset for nuclei originating from operation time-point samples of the 68 268 participants from the RYSA cohort included in this study. In the subset, we kept only the genes with at least 3 raw counts in at least 3 nuclei<sup>29</sup> and performed gene count normalization, variable 269 270 gene identification, data scaling, and PCA, as described above. To account for variation in gene expression driven by batch effect, we used Harmony v1.0.3<sup>32</sup> to integrate on batch and clustered 271 272 the nuclei with a standard Louvain algorithm, first 30 reductions from Harmony, and a resolution of 0.5. Cell-type annotations were performed using SingleR v1.8.1<sup>33</sup>, as described above, with 273 274 the SAT single-cell and snRNA-seq data from the previously published adipose tissue atlas by 275 Emont et al. as a reference<sup>34</sup>.

276

#### 277 Processing of the SAT VAT snRNA-seq data from the KOBS cohort

We aligned the VAT and SAT snRNA-seq data from the seven KOBS biopsies to the GRCh38 human genome reference with Ensembl annotations using CellRanger-arc -count v2.0.0<sup>35</sup> and CellRanger -count v6.1.1<sup>35</sup> for VAT and SAT, respectively. As the VAT sequencing from the seven KOBS VAT biopsies was generated using the 10x Genomics Multiome platform, we simultaneously profiled RNA and ATAC in each cell. We subset the data to include the nuclei

283 passing the QC for both RNA and ATAC, as recommended by CellRanger-arc, while only 284 including the VAT snRNA-seq data in the downstream analyses of this study. The KOBS SAT 285 snRNA-seq data were generated as a single modality and processed using the same reference 286 (GRCh38 human genome) but with the base software for CellRanger. Similarly to VAT, we only 287 included the nuclei from SAT that passed the recommended filtering from CellRanger. For the 288 remaining SAT and VAT nuclei, we separately further filtered out those containing ambient 289 reads using DIEM<sup>27</sup> through the removal of droplets from a debris cluster that reflected high 290 amounts of background RNA or low levels of nuclear RNA. To remove genetic doublets and 291 demultiplex the KOBS VAT Multiome samples and SAT snRNA-seq samples back to their 292 individuals of origin, we ran demuxlet<sup>30</sup> against the imputed genotype data of the individuals. 293 We removed all SAT and VAT cells that were not classified as singlets. We then ran  $DecontX^{29}$ 294 to remove contaminated reads within each droplet and filtered out nuclei with high levels of 295 ambient RNA, keeping those with UMIs over 200 and mitochondrial read percentage<10%. 296 These QC processes resulted in 3,216 nuclei for VAT and 3,516 nuclei for SAT from the same 297 individuals.

298

#### 299 Integration and clustering of SAT and VAT snRNA-seq data from the KOBS cohort

To find differences between SAT and VAT cell-type level gene expression from the KOBS biopsy samples, we performed integration between the tissues using Seurat v4.3.0<sup>28</sup>. The count data for nuclei from each tissue were first log-normalized using the NormalizeData function of Seurat<sup>28</sup>, with the default scaling factor of 10,000. Using these normalized count data, the top 2000 variable genes per tissue were calculated using the FindVariableFeatures function. Afterwards, we integrated the two tissues using canonical correlation analysis (CCA) with the

306	IntegrateData function of Seurat <sup>28</sup> . Following integration, the normalized read counts were
307	scaled with a mean of 0 and variance of 1. In the integrated samples with a total of 6,732 cells
308	from across the SAT and VAT snRNA-seq data, we performed PCA and identified clusters using
309	30 PCs and a resolution of 0.8.
310	
311	SnRNA-seq cell-type assignment and unique marker gene identification in the KOBS SAT
312	and VAT biopsy samples
313	We used SingleR v2.0.0 <sup>33</sup> with a previously published human single-cell adipose atlas <sup>34</sup> as a
314	reference to annotate the data at the individual cell level <sup>36</sup> . We ran the FindAllMarkers function
315	in Seurat <sup>28</sup> using <i>only.pos</i> = TRUE and min.cells.group=50 to identify marker genes of each cell-
316	type. We only included cell-types that consisted of at least 50 nuclei from the integrated tissues.
317	P-values were adjusted for multiple testing using the Bonferroni approach. To identify marker
318	genes unique per cell-type, we removed genes detected as marker genes (padj<0.05) for multiple
319	cell-types. These marker genes are shown in Supplementary Table 1.
320	
321	Tissue-specific marker gene identification
322	To find differences in the expression profiles of the three most prevalent SAT and VAT cell-
323	types (adipocytes, macrophages, and adipose stem and progenitor cells (ASPC)) in the KOBS
324	cohort, we identified three separate sets of cell-type marker genes. These three sets comprised
325	cell-type marker genes specific to SAT (MGSS), VAT (MGSV), and shared between the tissues
326	(MGSBT). We identified tissue-specific markers using the FindMarkers function of Seurat <sup>28</sup> ,
327	using a $\log_2$ fold change threshold of $\geq 0$ , to compare the SAT and VAT data of each cell-type. In
328	this tissue-specific marker gene identification, we only included the genes identified as unique

329	markers for each cell-type above. We adjusted p-values for multiple testing using FDR<0.05 for
330	the total number of cell-type-specific markers from above. Using this adjustment method, we
331	identified genes that are not only cell-type-specific but also show differential expression (DE)
332	between VAT (MGSV) and SAT (MGSS). We also identified a third group of marker genes for
333	each cell-type, i.e., those that showed no significant DE (FDR>0.05) between SAT and VAT.
334	We classified these as marker genes shared between the SAT and VAT tissues (MGSBT).
335	Overall, this resulted in 9 cell-type marker gene sets, i.e., three per cell-type (macrophages,
336	adipocytes, and ASPC) with no overlap between them. These 9 sets are listed in Supplementary
337	Table 2.
338	
339	Identification of enriched functional pathways
340	After identifying the 9 sets of cell-type marker genes, as described above, we ran WebGestalt <sup>37</sup>
341	to functionally characterize each set, using all genes with non-zero expression in at least two
342	cells in the cell-type <sup>34</sup> irrespective of the tissue origin, as the background. For each set, we tested
343	for significant (FDR<0.05) overrepresentation of genes from Gene Ontology (GO) biological
344	processes, cellular components, and molecular functions. We then identified the top pathway
345	genes (i.e. the genes that appeared in >1 significantly enriched pathways) by ranking each gene
346	by the number of times it appeared in the identified pathways.
347	
348	GWAS enrichment analysis of the cell-type marker genes
349	We assessed the 9 sets of tissue-specific and tissue-shared cell-type marker genes for significant
350	enrichments of genetic associations with BMI, WHRadjBMI, T2D, and MASLD using
351	MAGENTA v2.4 (Meta-Analysis Gene-set Enrichment of variaNT Associations) <sup>38</sup> .

2	5	$\mathbf{a}$
J	υ	2

353	We first downloaded publicly available European-only GWAS summary statistics for T2D <sup>39</sup> ,
354	while for WHRadjBMI and BMI, we used the UKB GWAS data we generated, as described
355	above. For every outcome, we then used the summary statistics to generate association scores for
356	each gene within the gene set based on the p-values of all variants within a 500kb upstream and
357	downstream window. Gene score-cutoff tests using the 75th percentiles of the scores of all genes
358	as cutoffs were performed to evaluate enrichment. While MAGENTA <sup>38</sup> filters out genes near one
359	another, we retained all genes per set in our analyses due to our small gene set sizes.
360	
361	Construction of marker gene -based regional and genome-wide PRSs for abdominal
362	obesity, BMI, and type 2 diabetes in UKB
363	We built both marker gene -based regional and genome-wide PRSs for waist-hip ratio adjusted
364	for BMI (WHRadjBMI), body mass index (BMI), and type 2 diabetes (T2D) for all unrelated
365	Europeans from UKB <sup>18</sup> . In our analysis, WHRadjBMI was used as a well-established proxy for
366	abdominal obesity <sup>11</sup> . The genome-wide PRSs for these traits were constructed using all SNPs
367	(see below), whereas the regional PRSs for each trait were created using the cis regional SNPs
368	(gene+/-500kb) of each of the autosomal marker gene sets separately (MGSBT, MGSS, and
369	MGSV) for the three main cell-types (adipocytes, macrophages, and ASPCs). We excluded the
370	set that contained shared SAT/VAT macrophage marker genes as it comprised only 9 genes, and,
371	therefore, it remained too small for reliable regional PRS building given the technical issues with
372	overfitting in PRS <sup>40</sup> . As WHRadjBMI is a highly sex-specific trait <sup>11</sup> , we also built the regional
373	WHRadjBMI PRSs for males (n= 88,988) and females (n=104,614) separately. Thus, in addition

to the genome-wide PRSs, we constructed 24 regional PRSs for WHRadjBMI and 8 regional

- 375 PRSs for T2D and BMI, respectively.
- 376

#### 377 Construction of WHRadjBMI and BMI PRSs

378 To construct the WHRadjBMI and BMI PRSs, we randomly selected 50% of the unrelated

379 Europeans from UKB (n=195,863) to generate GWAS summary statistics as the base data for the

380 PRS, and applied the PRS model in the remaining 50% of the cohort (i.e., the target group). For

the GWASs, the data were filtered to only retain variants with MAF >1% and INFO>0.8. We

also removed individuals with >1% of their genotypes missing or extreme heterozygosity, as

383 well as variants missing in >1% of the subjects or violating Hardy-Weinberg equilibrium from

the genotype data target group<sup>41</sup>. We conducted the GWASs of WHRadjBMI and BMI using

linear-mixed model approach of BOLT-LMM v2.3.6<sup>23</sup>, with age, age<sup>2</sup>, sex, the top 20 genetic

386 PCs, testing center, and genotyping array as covariates, where we applied a rank-based inverse

387 normal transformation for each outcome. For WHRadjBMI, given the sex-specificity of the

outcome<sup>11,42,43</sup>, we normalized twice, first in all individuals, and then for males and females

389 separately. Next, we fit the PRS models and computed the PRSs for WHRadjBMI and BMI for

390 the individuals in the target group using the split-validation mode from  $assosum^{44}$  (n=193,602)

and the filtered GWAS summary statistics as the base data for the PRS models.

392

#### **393 Construction of T2D PRSs**

To construct the T2D PRSs, we used the publicly available T2D GWAS summary statistics of Europeans without UKB from the DIAGRAM Consortium<sup>45</sup> as the base data. We built the PRS models using the target group genotype data employing PRScs<sup>46</sup>, with the provided LD matrix

from the Europeans in the 1000 Genomes Project as the LD reference, and applied the models tothe target group using PLINK.

399

#### 400 Calculating the explained variance in the trait by the PRSs

401 We calculated the incremental variance explained  $(R^2)$  in the trait against a null model containing

402 the covariates of age,  $age^2$ , the top 20 genetic PCs, testing center, genotyping array, and sex

403 using lassosum<sup>44</sup>. For T2D, we calculated a delta AUC, similarly to the incremental variance

404 from above.

405

406 We evaluated the significance of each regional PRS by ranking the observed incremental  $R^2$  or

delta AUC against the incremental  $R^2$ /delta AUC of 10,000 PRSs similarly built from the *cis* 

408 regional variants of random gene sets of the same size as in the regional PRS set, using all

409 expressed genes (counts>=1 in at least 2 nuclei)<sup>34</sup> in the cell-type of interest as a background.

410 The P-value was defined as the number of permutations in which the  $R^2$ /delta AUC is larger than

411 the calculated PRS divided by 10,000.

412

#### 413 Partitioned heritability assessment of PRS-enriched gene sets

We performed a partitioned heritability analysis with LD Score regression (LDSC)<sup>47,48</sup> to assess the genes with WHRadjBMI R<sup>2</sup> enriched PRSs for enrichment in the WHRadjBMI heritability relative to the genome, similarly as in Finucane et al.<sup>48</sup>. Briefly, we used LDSC to estimate the LD scores from all SNPs in the genome, as well as from all SNPs residing with the *cis* regions of each PRS-enriched gene set. Scores were constructed in 76,758 randomly selected, unrelated Brits from UKB (35,257 males, 41,501 females) for computational efficiency, and as in Finucane

420	et al. <sup>48</sup> , we only included SNPs with MAF>5% for the analysis. We then used the same
421	WHRadjBMI GWAS summary statistics as in the PRS analysis to compute the WHRadjBMI
422	heritability of the genome and marker gene annotations and test each marker annotation for
423	significant (p<0.05) heritability enrichment, defined as the proportion of heritability divided by
424	the proportion of the genome from the annotation <sup>48</sup> .
425	
426	Longitudinal RNA- and ATAC-sequencing during human SAT primary preadipocyte
427	differentiation
428	We previously performed a longitudinal adipogenesis experiment using human SAT primary
429	preadipocytes and generated longitudinal bulk RNA- and ATAC-seq data on samples collected at
430	the 0 day (0d), 1d, 2d, 4d, 7d, and 14d timepoints, with 4 isogenic replicates per timepoint, as
431	described earlier <sup>7,49</sup> . Peaks from the ATAC-seq were filtered to remove blacklisted regions and
432	identify consensus peaks, as described in detail previously <sup>7</sup> .
433	
434	Differential expression (DE) analysis across six adipogenesis time points
435	We examined the longitudinal expression patterns of the top pathway-enriched genes from the
436	adipocyte MGSS set (n=43 genes) using ImpulseDE2 v0.99.10 <sup>50</sup> . We used the runImpulseDE2
437	function with default parameters and boolCaseCtrl=FALSE, boolIdentifyTransients=TRUE, and
438	<i>scaNProc</i> =1. P-values were corrected for multiple testing using FDR<0.05. As the adipogenesis
439	experiment was conducted in SAT preadipocytes, we only ran this DE analysis for genes in the
440	adipocyte MGSS set.
441	

#### 442 Identification of longitudinally co-expressed clusters of adipocyte pathway genes and their

#### 443 regulators during human adipogenesis

444 To search for longitudinal co-expression patterns among the adipocyte pathway genes across

- human adipogenesis, we ran DPGP  $v0.1^{51}$  to cluster genes by their expression trajectories. We
- 446 ran DPGP with the timepoint data of the adipogenesis experiment described above and only
- 447 included the genes that we identified as significantly longitudinally DE (FDR<0.05) during

448 human adipogenesis from ImpulseDE $2^{50}$  and expressed across adipogenesis (n=42).

449

## 450 Identification of co-accessible peaks during human adipogenesis within the *cis* region of

451 *SREBF1* 

452 To identify co-accessible peaks in the SREBF1 cis region during human adipogenesis, we used

453 the longitudinal ATAC-seq data from the human SAT primary preadipocyte differentiation

454 experiment described above. We first identified SAT adipocyte peaks within  $\pm 500$  kb of

455 SREBF1, a key SAT adipocyte marker gene. To determine temporal differential accessibility

456 (DA) of these SAT peaks and identify clusters of longitudinally co-accessible peaks, we ran

457 ImpulseDE2<sup>50</sup> as described above on the accessibility counts for the peaks, subset the data to the

458 peaks passing an FDR threshold < 0.05, and then clustered the DA peaks (n=120) using DPGP<sup>51</sup>,

- as described above. We only included the clustered peaks that passed a cluster assignment
- threshold of probability>0.9.

461

# 462 Identification of WHRadjBMI GWAS variants within the longitudinally co-accessible SAT 463 adipocyte peaks in the *SREBF1 cis* region

464	We next investigated the 5 longitudinally co-accessible SAT adipocyte peaks discovered in the
465	SAT adipogenesis experiment within the cis regions of SREBF1 for WHRadjBMI GWAS
466	variants. Accordingly, we overlapped the positions of the genome-wide significant ( $p < 5 \times 10^{-8}$ )
467	WHRadjBMI GWAS variants using the summary statistics from a previously published
468	extensive WHRadjBMI GWAS of the GIANT–UKB meta-analysis <sup>52</sup> with the positions of the
469	co-accessible SAT adipocyte peaks.
470	
471	Identification of adipocyte MGSS genes by risk allele status of the WHRadjBMI GWAS
472	variants in the SREBF1 region
473	We tested whether the risk allele carrier status of the seven WHRadjBMI GWAS variants
474	residing in the longitudinally co-accessible SAT peaks in the SREBF1 region affects the SAT
475	adipocyte expression of SREBF1 and other SAT adipocyte markers genes in trans using RYSA
476	SAT adipocyte snRNA-seq data. Briefly, for each variant, we labeled each individual from the
477	RYSA cohort with zero copies of the GWAS trait-increasing allele as "non-carriers" and those
478	with one or two copies of the trait-increasing allele as "carriers," and then labelled each
479	individual cell in the cohort as coming from a "carrier" or a "non-carrier" individual. We subset
480	the SAT snRNA-seq data to adipocytes and ran the FindMarkers function in Seurat <sup>28</sup> with
481	logfc.threshold = 0 between cells labeled "carriers" and "non-carriers" while only testing the
482	adipocyte MGSS gene set and adjusting the p-values for multiple testing using FDR<0.1. We
483	repeated this for each of the seven SNPs. For each trans gene set, we built module scores using
484	the AddModuleScore function in Seurat v4.3. $0^{28}$ in SAT adipocytes from the RYSA cohort to
485	determine the average expression across all adipocytes between carriers and non-carriers.
486	

#### 487 Identification of adipogenesis open chromatin peaks by cell-type

- 488 To identify upregulated and shared peaks at the preadipocyte and adipocyte stages of human
- 489 adipogenesis, we ran DESeq $2^{53}$  on the raw peak count data generated using ATAC-seq at the day
- 490 0 and 14 time points in the SAT adipogenesis experiment described above. Peaks with a
- 491 log<sub>2</sub>FC>0.1 and Bonferroni adjusted P (padj)<0.05 were classified as upregulated in
- 492 preadipocytes, while the peaks with a  $\log_2 FC \le 0.1$  and padj  $\le 0.05$  were classified as upregulated
- 493 in adipocytes. The remaining peaks were classified as shared between the human preadipocytes
- and adipocytes.
- 495

## 496 Construction of abdominal obesity PRSs in UKB for the adipocyte marker genes affected

#### 497 by the seven regional *SREBF1* variants in *trans*

498 To investigate the abdominal obesity risk of the regional variants in the *trans* gene sets, the 499 adipocyte expression of which is up- or downregulated by the *SREBF1* variant carrier status, we 500 constructed partitioned PRSs using the *cis* regional SNPs of these *trans* gene sets. The PRSs 501 were built separately for each up/downregulated trans gene set for the seven SNPs, resulting in 502 14 total unique PRS sets. As abdominal obesity risk differs by sex<sup>42,43</sup>, we analyzed these 503 partitioned abdominal obesity PRSs in all individuals, females, and males separately. Due to the 504 small region sizes and to allow for fine-grained control of the SNPs comprising each PRS, we 505 used a clumping and thresholding (C+T) approach with PLINK v1.9 for the PRS construction, 506 with the same GWAS summary statistics for WHRadjBMI described above, as the base data. We 507 partitioned the remaining 50%, not used for the GWAS, into two cohorts, a 30% test group 508 (n=115,120) for performing the LD clumping and learning the optimal thresholding parameter, 509 and a 20% validation group (n=76,758) to apply the learned PRS model and perform

downstream analyses. We performed QC on the test and validation genotype data, similarly asdescribed above.

512

513 To build the partitioned abdominal obesity PRSs, we first performed LD clumping on the full 514 genotype data of the test groups with PLINK v1.9 using R<sup>2</sup> of 0.2 and window size of 250 kb, 515 and built the PRSs from the independent SNPs passings p-value thresholds ranging from  $5 \times 10^{-8}$ 516 to 0.5 to empirically determine the p-value threshold that maximizes the incremental variance 517 explained in WHRadjBMI in the test group. Next, for each *trans* gene set, we identified all C+T 518 SNPs that landed in the adipocyte upregulated open chromatin peaks (described earlier), using 519 the empirically determined p-value thresholds of p<0.05, p<0.005, and p<0.1 for all individuals, 520 females, and males, respectively. To avoid direct SREBF1 cis effects on the abdominal obesity 521 risk, we removed the seven SNPs in the SREBF1 region as well as any C+T SNPs in LD 522  $(R^2>0.1)$  with any of these seven SNPs from these partitioned PRS analyses. We computed PRSs 523 for the sets that contained  $\geq 5$  valid SNPs. As explained before, the incremental variance ( $\mathbb{R}^2$ ) 524 was calculated for each PRS and compared against 10,000 permuted PRSs built from the same 525 numbers of C+T SNPs.

526

After computing individual level WHRadjBMI PRSs, we compared the polygenic risk, i.e., the PRS magnitudes, in the regional PRSs of the *trans* gene sets between the *SREBF1* variant carriers and non-carriers. First, we classified individuals in the UKB PRS cohort into "carriers" or "non-carriers" in the same way as in the RYSA cohort. Next, we performed a two-sided Wilcoxon test between the WHRadjBMI PRSs of the carriers and non-carriers within each group while correcting for multiple testing using Bonferroni.

#### 533 Results

#### 534 Study design

535 The summary of the study design is shown in Supplementary Figure 1. Briefly, by first

- identifying cell- and tissue-type expression profiles that drive functional differences between the
- two key human fat depots, subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)
- and genetic enrichments of these SAT and VAT -specific genes for abdominal obesity, we
- 539 discovered a transcription factor (TF) gene preferentially involved in numerous functional SAT
- 540 pathways over VAT. We then further investigated the cell-type level regulatory mechanisms of
- this TF, and discovered that the regional abdominal obesity GWAS variants of this TF affect the
- adipocyte expression of tens of SAT adipocyte marker genes in *trans* in the independent RYSA
- 543 cohort. Finally, we confirmed the identified *trans* effects of the TF variants by comparing the

544 partitioned regional PRSs of the *trans* genes by their risk allele carrier status at the biobank level

545 (Figure 1a).

546

## 547 Marker gene analysis reveals distinct differences between SAT and VAT in cell-type level 548 expression profiles

549 To elucidate cell-type level functional differences between SAT and VAT, the two main human

550 fat depots<sup>1</sup>, we first investigated SAT and VAT gene expression profiles at the cell-type

resolution using SAT and VAT biopsies from the same individuals (Figure 1b-c). These dual

- tissue fat depot data from the same individuals, which reduce confounding by phenotypic
- 553 differences between the donors of the SAT and VAT biopsies, enabled us to identify unique SAT
- and VAT cell-type marker genes, or genes that are differentially upregulated in only one cell-
- type, and also unique to each adipose tissue depot in their marker gene status (see Methods).

556 Figure 1d shows the adjpocyte cell-type markers distributed by tissue specificity. Supplementary 557 Table 1 shows the identified unique cell-type marker genes for all SAT and VAT cell-types after 558 integrating the single nucleus level data of the two tissues. As small differences often drive 559 depot-specific gene and functional patterns<sup>42</sup>, we sought to study not only differences in 560 expression between the depots but also shared transcriptional profiles, as this may elucidate the 561 connection and shared characteristics between the tissues. Thus, from each cell-type marker set, 562 we identified sets of unique marker genes specific to each tissue and shared across the two, 563 resulting in 3 sets: marker genes specific to SAT (MGSS), marker genes specific to VAT 564 (MGSV), and marker genes shared between tissues (MGSBT) (Supplementary Table 2). We 565 focused our analyses on the three major shared cell-types between SAT and VAT, i.e., adipose 566 stem and progenitor cells (ASPCs), adipocytes, and macrophages due to their functional pathway 567 enrichments (see below) and highest number of nuclei available across the two tissues. The 568 MGSS sets contained 244, 208, and 250 unique cell-type marker genes for ASPCs, adipocytes, 569 and macrophages; the MGSV sets 131, 225, and 224; and the MGSBT sets 112, 155, and 9, 570 respectively (Supplementary Table 2). 571 572 Shared and tissue-specific marker genes are enriched for genetic signals of obesity and 573 related CMDs

As both adipose tissue depots are known to be impacted by obesity and related disorders<sup>2,4,5,54</sup>, we first examined these marker gene sets for GWAS variant enrichments of obesity and related CMDs. Accordingly, we tested the variants in the *cis* regions (±500kb) of the three sets per celltype in three cell-types, MGSS, MGSV, and MGSBT (nine total sets), for enrichment of BMI, abdominal obesity (using WHRadjBMI as a proxy), and type 2 diabetes (T2D) GWAS signals

579 using GWAS summary statistics and the MAGENTA tool (see Methods). We observed

significant enrichments (FDR<0.05) in the ASPC MGSBT for BMI, and in the adipocyte MGSS</li>
for T2D and WHRadjBMI (Table 1), while no enrichments were detected for any cell-types with
the MGSV sets.

583

Next, we assessed each marker gene set for enrichment of polygenic risk for these obesity and 584 585 related traits. We evaluated the predictive power of annotated polygenic risk scores (PRSs) for 586 WHRadjBMI, BMI, and T2D from the cis regional variants of each set in the large UK Biobank 587 (UKB) cohort. We first built PRSs for all individuals for each cell-type set and found that the 588 regional PRS constructed for the adipocyte MGSS gene set was a significant predictor  $(p_R^2 < 2.23 \times 10^{-308})$  of WHRadjBMI. Next, we followed up on these WHRadjBMI PRS findings 589 590 using permutations. Of our 10,000 permutation scores, each similarly built from SNPs residing in 591 the *cis* regions of the same number of randomly selected adipocyte expressed genes from either 592 tissue, we observed only 0.82% to have an incremental R<sup>2</sup> greater than or equal to that of the 593 adipocyte MGSS WHRadjBMI PRS (R<sup>2</sup>=1.20%; p<sub>perm10.000</sub>=0.0082) (Figure 2; Supplementary 594 Table 3). Due to this observed enrichment in variance explained of WHRadjBMI, which is 595 known to be a sex-dimorphic trait<sup>43,55</sup>, we also constructed these regional WHRadjBMI PRSs for 596 females and males separately. We observed the enrichment in all individuals to be driven by 597 females as the WHRadjBMI PRS constructed for the cis regional variants of the adipocyte MGSS genes was significantly enriched ( $R^2=2.12\%$ ,  $p_{perm10.000}=0.0101$ ) in females, but not in 598 599 males (Figure 2; Supplementary Table 3). In line with previous connections with visceral adipose tissue<sup>56,57</sup>, we found that the variance explained for T2D was significantly enriched for the 600 601 adipocyte MGSV gene set (Delta AUC=1.16%, p<sub>perm1.000</sub>= 0.036). No other significant

602	enrichments in variance explained were detected for BMI or T2D in our PRS analyses, and no
603	other significant enrichments were detected for other cell-types for WHRadjBMI.
604	
605	After identifying the adipocyte MGSS WHRadjBMI PRS results as significantly enriched for
606	variance explained for all individuals and females, we performed a partitioned heritability
607	analysis to further corroborate these enrichments. We observed that the heritability $(h^2)$ of
608	WHRadjBMI from the SNPs in the cis regions of the adipocyte MGSS set was significantly
609	enriched in all individuals (h <sup>2</sup> enrichment=2.21, p=0.00150) and in females (h <sup>2</sup> enrichment=2.47,
610	p= $1.54 \times 10^{-4}$ ), in line with the regional PRS analysis.
611	
612	Taken together, the GWAS and PRS enrichments and significant heritability enrichment results
613	highlight the adipocyte MGSS gene set as particularly important for the polygenic risk of
614	abdominal obesity.
615	
616	Identification of SREBF1 as the key SAT-enriched adipocyte marker gene
617	After identifying WHRadjBMI PRS enrichments in the adipocyte MGSS set, we explored the
618	functional differences of the SAT and VAT gene sets. For each major cell-type, we tested for
619	overrepresentation of genes in Gene Ontology (GO) categories using all three sets, MGSS,
620	MGSV, and MGSBT (Supplementary Tables 4-10). There were no significant functional
621	pathways for the macrophage MGSS and MGSBT sets. Among the adipocyte MGSV and
622	MGSBT gene sets, we detected 170 and 9 significant pathways, respectively (FDR<0.05).
623	Among the pathways of the adipocyte MGSV gene set, 103 (61%) and 98 (58%) pathways
624	included the well-known insulin metabolism genes, INSR and IRS2, respectively. However, the

strongest adipose tissue function-related pathway enrichments were observed in the adipocyte
MGSS set (FDR<0.05), including regulation of fatty acid metabolic process, positive regulation</li>
of triglyceride metabolic process, and neutral lipid metabolic process amongst other breakdownof-molecule centered processes (Supplementary Table 4).

629

630 In more detail, we found 23 significant functional pathways (FDR<0.05) for the adjpocyte 631 MGSS set (Figure 3a; Supplementary Table 4). Notably, we observed a strong presence of the 632 master transcription factor (TF) of adipogenesis and fatty acid biosynthesis, SREBF1<sup>14</sup>, in these 633 MGSS pathways. Of the 23 enriched functional pathways for adipocyte MGSSs (FDR< 0.05), 20 634 (87%) included *SREBF1*, making it the most prevalent pathway gene, and thus supporting its 635 importance in the SAT adipocyte function. Consistent with the known role of SREBF1 as an adipose master TF<sup>14,58,59</sup>, we also observed that 8 of the most prevalent pathway genes (genes 636 637 present in 8 or more pathways) in the adipocyte MGSS gene set are predicted transcription targets of SREBF1 that have also previously been linked to obesity, including LEP<sup>60</sup> and FASN<sup>61</sup> 638 639 (Figure 3b).

640

Figure 3c shows how this key MGSS TF, *SREBF1* exhibits a substantially higher adipocyteenriched expression level in SAT than VAT. We confirmed the adipocyte unique marker gene status of *SREBF1* in SAT snRNA-seq in the independent RYSA cohort (n=68) (average  $\log_2$  fold change=0.473,  $p_{adj}<2.23\times10^{-308}$ ), thus replicating its role as a significant SAT specific marker. Additionally, we replicated the lack of preferential expression of *SREBF1* in VAT adipocytes, in an independent VAT snRNA-seq data from another cohort<sup>34</sup> comprising obese individuals

• 1

1 . 1

RODGILLE

1

1

1 1

1

 $(\mathbf{D})$   $(\mathbf{G}, \mathbf{Q})$ 

~ - -

647	(BMI>30) of European descent (n=5), which, similarly to the KOBS VAT samples, showed low,
648	diffuse expression of SREBF1 in all VAT cell-types (Supplementary Figure 2).
649	
650	Identification of temporally co-expressed adipocyte MGSS pathway genes during human
651	adipogenesis
652	To link these functionally enriched MGSS genes to adipose tissue development and
653	differentiation, we examined the temporal expression of the key pathway genes within the
654	adipocyte MGSS set during human primary SAT preadipocyte differentiation (i.e.,
655	adipogenesis). We first identified 43 MGSS genes that contributed to more than one significantly
656	(FDR<0.05) overrepresented pathway (Supplementary Table 4) and then found that the 42 of the
657	43 genes, expressed during SAT adipogenesis, were all longitudinally differentially expressed
658	(DE) (FDR<0.05) during differentiation (Figure 3d). To link together genes with similar
659	temporal transcription patterns, we clustered these longitudinally expressed genes using DPGP <sup>51</sup>
660	into 8 groups of temporally co-expressed genes (Figure 3d, Supplementary Table 11). Of note,
661	we observed SREBF1 to cluster with two previously described obesity genes, LEP <sup>60</sup> and FASN <sup>61</sup>
662	(Figure 3d), further supporting the coordinated role of SREBF1 as a master TF with other key
663	adipocyte marker genes.
664	

# 665 Longitudinally differentially accessible peaks, co-accessible in the *SREBF1* region during 666 adipogenesis, harbor abdominal obesity GWAS variants

To elucidate the genetic regulatory role of *SREBF1* in abdominal obesity, we first searched for

open chromatin peaks with similar temporal accessibility patterns in the *cis* region of *SREBF1* 

during human SAT adipogenesis (Figure 4a). We detected 129 peaks in the *cis* region ( $\pm$  500 kb)

670 of SREBF1 and found 120 (93%) to be longitudinally DA over the 14-day preadipocyte 671 differentiation data (FDR<0.05), which we then clustered into 10 groups using DPGP<sup>51</sup> 672 (Supplementary Table 12). The clusters with peaks remaining after thresholding at a cluster 673 assignment probability>0.9 are shown in Supplementary Figure 3. We focused on cluster 4, 674 which contains 5 peaks with similar trajectories over the 14-day differentiation (Figure 4b). 675 676 To determine whether these five co-accessible peaks from cluster 4 in the *SREBF1* region 677 (Figure 4b) are involved in genetic risk of abdominal obesity, we next investigated them for overlaps with WHRadjBMI GWAS variants. Using the large, previously published GWAS 678 679 summary statistics for WHRadjBMI from GIANT-UKB<sup>52</sup>, we identified 7 GWAS SNPs within 680 these 5 peaks (Table 2). Of the 7 SNPs, rs4924755, rs7224725, and rs9944423 were significant (p<5×10<sup>-8</sup>) in all individuals, driven by females (also significant in only females); rs35104205 681 682 was significant in all, females, and males; and rs12948060, rs4646347, and rs4646346 were 683 significant only in males, reflecting the well-known sex effects of the WHRadjBMI trait (Table 684 2). Furthermore, rs4924755, rs7224725, rs9944423, and rs35104205 are also significant GWAS 685 SNPs ( $p < 5 \times 10^{-8}$ ) for the serum total triglycerides in all individuals from the European ancestry GLGC lipid GWAS<sup>62</sup>. 686

687

We observed tight LD patterns (R<sup>2</sup>>99%) among three of the 7 SNPs, rs12948060, rs4646347,
and rs4646346, and separately among two SNPs rs7224725 and rs9944423, indicating 4 separate
regional WHRadjBMI signals (Figure 4c). These results show that the 5 co-accessible peaks in
the *SREBF1* region contribute to the genetic risk of abdominal obesity.

692

# Risk allele status for the abdominal obesity GWAS SNPs in the *SREBF1 cis* region affects SAT adipocyte expression of *SREBF1* and more than hundred SAT adipocyte marker genes

696 We hypothesized that these seven abdominal obesity GWAS variants, which reside in the *cis* 

697 regulatory region of *SREBF1*, may influence the downstream expression of important adipocyte

698 genes in *trans*. To address this hypothesis, we investigated whether the risk allele status of the

699 seven WHRadjBMI GWAS SNPs in the SREBF1 cis region impacts SAT adipocyte expression

of *SREBF1* and downstream, the adipocyte expression of other adipocyte MGSSs, using

701 independent SAT snRNA-seq data from another European bariatric surgery cohort, RYSA

702 (n=68) (see Methods). We identified *SREBF1* and 146 other adipocyte MGSS genes, for which

the adipocyte expression is significantly affected by the risk allele carrier status of one or more

of these seven WHRadjBMI GWAS variants in *trans* (see Methods) (Supplementary Table 13).

Due to the tight LD ( $R^2$ >99%) among rs12948060, rs4646347, and rs4646346, as well as among

SNPs rs7224725 and rs9944423 (Figure 4c), their results are identical.

707

In more detail, we observed that the SAT adipocyte expression of *SREBF1* was significantly

impacted by each of the seven WHRadjBMI GWAS variants, being higher expressed in the risk

allele carriers of rs12948060, rs35104205, rs4646347, and rs4646346, and lower expressed in the

risk allele carriers of rs4924755, rs7224725, and rs9944423. The three SNPs in tight LD

(rs12948060, rs4646347, and rs4646346) had the largest number of genes (n=115 genes) with

r13 significantly higher expression in the risk allele carriers (Supplementary Table 13), while the

SNPs rs7224725 and rs9944423 in LD ( $R^2$ >99) had the fewest (n=23 genes) (Supplementary

Table 13). We found that the variant rs4924755 impacted the largest number of genes with lower

716	expression in the risk-allele carriers (n=48 genes), including multiple functionally important
717	adipose genes, e.g., FASN, AGPAT2, DGAT1, in line with the downregulation of SREBF1 in
718	these carriers (Supplementary Table 13). The risk allele carrier status of this variant rs4924755
719	also associated with upregulation of numerous key adipose genes, such as PLIN1, PLIN4, and
720	LIPE (Supplementary Table 13). We show the functional pathway enrichments of the gene sets
721	affected by the risk allele carrier status in Supplementary Tables 14-16.
722	
723	We also built module scores in the independent RYSA cohort using the SAT adipocyte
724	expression of the up/down regulated trans genes by the risk allele status of the of the SREBF1
725	abdominal obesity GWAS SNPs (Figure 5a-b, Supplementary Figure 4). These average
726	expression results of the trans genes further demonstrate the significant, wide-spread trans
727	effects of the SREBF1 abdominal obesity GWAS SNPs on SAT adipocyte expression. Taken
728	together, our results suggest that the WHRadjBMI GWAS SNPs in the cis region of SREBF1
729	affect SAT adipocyte expression of the major adipose tissue TF, SREBF1, and downstream of
730	that, the adipocyte expression of 146 genes, comprising 70% of all adipocyte MGSS genes and
731	including multiple key adipocyte MGSS genes.
732	
733	Adipocyte open chromatin variants in <i>cis</i> regions of the <i>trans</i> gene sets are enriched for
734	variance explained in WHRadjBMI and their PRSs differ by the risk allele carrier status of
735	the SREBF1 abdominal obesity GWAS SNPs
736	We hypothesized that the <i>trans</i> gene sets we identified had downstream effects on the polygenic

risk of abdominal obesity by the risk allele carrier status of the *SREBF1* abdominal obesity

738 GWAS SNPs. Accordingly, we first examined the genetic risk contributions from the *trans* genes

739 sets by constructing their regional PRSs for WHRadjBMI in UKB from the SNPs that fell in 740 adipocyte open chromatin peaks in the *cis* regions of each *trans* gene set (see Methods). We 741 found, through 10,000 permutations, that 12 out of the 21 PRSs which were built from variants 742 from upregulated *trans* gene sets were significantly enriched (p<sub>perm10,000</sub><0.05) for incremental 743 variance explained in abdominal obesity (Figure 5c, Supplementary Table 17), as were 6 out of 744 the 10 PRSs built from variants from downregulated *trans* gene sets (Figure 5c, Supplementary 745 Table 18), indicating that the regulatory regions of these *trans* regulated genes are important for 746 abdominal obesity. 747 748 Next, we classified the UKB individuals as the carriers and non-carriers of the seven SREBF1 749 abdominal obesity GWAS risk alleles in the same way as in the RYSA adipocyte expression 750 analysis and then compared the WHRadjBMI PRSs of the *trans* gene sets between the carriers 751 and non-carriers in UKB to further assess the *trans* regulatory nature of the carrier status. We 752 found that the SREBF1 cis regional variants exhibit significant differences in the magnitude of 753 the regional WHRadjBMI PRSs of 10 out of the 21 upregulated trans gene sets between the 754 carriers and non-carriers of the corresponding SREBF1 abdominal obesity GWAS SNP risk 755 allele (Wilcoxon padj<0.05) (Supplementary Table 17), thus independently confirming the

observed *trans* effects in RYSA adipocytes at the population level in UKB. Similarly, we found

that 4 out of 10 downregulated *trans* gene sets also show significant PRS differences (Wilcoxon

padj< <0.05) between the carriers and non-carriers (Supplementary Table 18). Figure 5d shows

these significant differences between the regional WHRadjBMI PRSs of the trans genes by the

risk allele carrier status of one of the 7 *SREBF1* WHRadjBMI GWAS SNPs, rs4924755, and

761 Supplementary Figure 5 illustrates similar significant WHRadjBMI PRS differences with several

762	of the other SNPs. We also observed sex-specific differences in these PRS results (Figure 5c-d,
763	Supplementary Tables 17-18), in line with the well-known sex differences in abdominal obesity.
764	Overall, our results discover SREBF1 for SAT adipocyte function and genetic risk of abdominal
765	obesity via variant-specific trans effects on numerous adipocyte trans genes.
766	
767	
768	
769	
770	
771	
772	
773	
774	
775	
776	
777	
778	
779	
780	
781	
782	
783	
784	

#### 785 Discussion

786 Despite prevailing cellular heterogeneity within and between the two major human fat depots, 787 SAT and VAT, the underlying genes, functional pathways, and epigenetic and genetic factors 788 explaining these differences have remained largely elusive at the cell-type resolution  $^{63-65}$ . 789 Previous studies have reliably connected SAT and VAT to obesity and related cardiometabolic metabolic diseases (CMDs)<sup>2,4,5,54</sup>, but the distinct contributions of each fat tissue and their cell-790 791 types to disease predisposition are less well understood. Here, we integrated human single-cell 792 level RNA data to comprehensively compare SAT and VAT at the transcriptomic level. By 793 deriving tissue- and cell-type-specific marker gene sets (MGSS, MGSV, and MGSBT) for each 794 of the three major adipose cell-types, we establish which unique cell-type marker genes are 795 shared and which ones are specific to adipocytes, ASPCs, and macrophages in SAT versus VAT 796 and how these genes contribute to the key cell-type functions and genetic risks to CMDs. Upon 797 assessing the GWAS associations, partitioned polygenic risk scores, and heritability estimates in 798 these cell-type marker gene sets, we highlighted the importance of the adipocyte marker genes 799 unique to the SAT depot for genetic predisposition to abdominal obesity, led by the major 800 adipose TF gene, SREBF1, observed in 87% of the functional pathways unique to the SAT 801 adipocyte marker genes. We also discover regional, longitudinally co-accessible peaks across 802 SAT adipogenesis at this SREBF1 locus, which harbor seven GWAS variants associated with WHRadjBMI, a well-established abdominal obesity proxy<sup>11</sup>. Next, we show that the risk allele 803 804 carrier status of these seven WHRadjBMI GWAS variants affects SAT adipocyte expression of 805 SREBF1 and 146 other functionally enriched SAT adjpocyte marker genes (i.e., 70% of all SAT 806 adipocyte marker genes) in the large independent SAT snRNA-seq data set from the RYSA 807 cohort, identifying profound cell-type level downstream effects of this adipose major TF in

808 *trans.* Lastly, we confirm this result independently in the UK Biobank by demonstrating that the 809 partitioned abdominal obesity PRSs of the adipocyte *trans* gene sets differ by the risk allele 810 carrier status of the *SREBF1* abdominal obesity GWAS variants. Taken together, our study 811 discovers abdominal obesity GWAS variants in the *cis* region of *SREBF1* that act in *trans* as 812 drivers of downstream adipocyte gene expression of more than a hundred of genes.

813

814 Previous studies have shown that excess VAT leads to increased risk for MASLD, insulin resistance, and coronary artery disease<sup>56,57</sup> and that excess SAT is correlated with an increase in 815 oxidative stress and inflammation<sup>66</sup>, but the cell-type and gene level mechanisms underlying 816 817 these different depot-specific contributions to CMD predispositions are not well understood. In 818 our study, by leveraging the snRNA-seq data from the same KOBS participants' SAT and VAT 819 biopsies, we characterize gene expression without inter-individual bias and separate cell-type 820 marker genes into shared and tissue-specific gene sets. While previous studies have similarly 821 discerned both partial differences in the cell-type identities and functionalities of shared cell-822 types<sup>67–70</sup>, our study further examines these tissue-shared and specific profiles in the context of 823 the CMD risks. Through constructing partitioned polygenic risk scores which isolate the 824 polygenic risk contributions from the regional variants in the genes at the center of these tissue 825 profiles, we discern enrichment for the abdominal obesity PRS from the adipocyte SAT-specific 826 marker genes, further supported by our WHRadjBMI heritability analysis of the adipocyte 827 MGSS gene set by LD score regression. We additionally confirm previously known connections of VAT to T2D<sup>56,57</sup> through identifying enrichment for T2D PRS from the adipocyte VAT-828 829 specific marker genes. Overall, our genetic results suggest that the genetically regulated 830 transcriptional differences between the two human fat depots link to substantial distinctions

between the tissue- and cell-type level contributions to CMDs. When investigating the role of
sex as a biological factors, we also found that the regional PRSs constructed from the local
variants of the adipocyte SAT-specific marker genes are highly enriched predictors of
WHRadjBMI in all individuals and females, in line with the previously established heritability
enrichments of WHRadjBMI in SAT, sex-dimorphisms of WHRadjBMI, and the causality

836 estimates of WHRadjBMI for MASLD<sup>71,72</sup>.

837

838 We further elucidate patterns of tissue and cell-type specificity among the two fat depots through 839 evaluating the functional enrichments among the SAT and VAT marker gene sets. In line with previously identified cellular heterogeneity between the two tissues<sup>34,70</sup>, we observe that the 840 841 adipocyte SAT-specific marker genes are enriched for genes involved in the metabolism of fatty 842 acids, triglycerides, and glucose, while the adipocyte marker genes shared across the depots, or 843 specific to VAT exhibited enrichment in molecular movement and lipid localization. These 844 results are supported by previous studies that found that VAT is important for a flux of fatty acid 845 buildup<sup>73</sup>, which suggests that while VAT would be important for the long-term fat storage-846 oriented properties of adipose tissue, SAT may be more influential for the metabolic activities, 847 such as rapid-expansion of fat molecules, and flexible breakdown of fat-related molecules. In 848 particular, we identified *SREBFI* as the key to the adipocyte MGSS functional pathways, found 849 in 87% of the SAT-specific significant functional pathways. SREBF1 is the fatty acid synthesis 850 master TF and a key regulator of transcriptional control for adipogenesis<sup>14,15</sup>. It also regulates the transcription of several obesity-involved gene pathways<sup>15</sup>. In our study, we observed a distinct 851 852 upregulation of *SREBF1* adjpocyte expression in SAT, compared to its sparse and diffuse 853 expression across all cell-types in VAT, a pattern that we replicated in independent SAT and

854 VAT cohorts<sup>34</sup>. Consistent with our genetic assessments, these patterns suggest that the 855 contributions to abdominal obesity may be more pronounced in SAT adipocytes than in the VAT 856 counterparts. Although other studies have shown low diffuse expression levels of SREBF1 across multiple cell-types in VAT<sup>58</sup>, our study discovers *SREBF1* as a unique adipocyte-specific marker 857 858 gene in SAT involved in numerous functional SAT pathways not enriched among the VAT 859 adipocyte marker genes, which may explain functional differences between SAT and VAT given 860 the well-established regulatory role of this master TF. Furthermore, we present differences in 861 SAT adjpocyte gene expression of the key adjpocyte marker genes between the carriers and non-862 carriers of the abdominal obesity GWAS variants in the *cis* region of *SREBF1*, supporting the 863 evidence of SREBF1 as a master transcription factor with more than a hundred important target 864 genes in SAT adjpocytes. Taken together, we find that differences in cell-type-specific gene 865 expression between SAT and VAT link to differences in SAT and VAT function and identify 866 one such gene, *SREBF1* that is present in most SAT adipocyte-specific pathways and absent in VAT adipocyte-specific pathways. 867 868

869 When investigating the genetic contribution of the *SREBF1* region to abdominal obesity, we 870 found that co-accessible adipocyte ATAC-seq peaks in the cis region of SREBF1 harbor multiple 871 genome-wide significant WHRadjBMI GWAS variants, including variants with sex-specific associations, thus linking to the well-established sex-dimorphism of the abdominal obesity<sup>11,43,55</sup>. 872 873 We also discovered using SAT adipocyte expression data from the large independent RYSA cohort that these WHRadjBMI GWAS risk variants are associated with expression of 146 874 875 adipocyte marker genes specific to SAT, including *SREBF1*. These adipocyte marker genes, 876 impacted by the risk allele carrier status, are also functionally enriched for important adipocyte

877 functions. Next, we further confirm these single cell-level *trans* effects by building partitioned 878 abdominal obesity PRSs of these *trans* gene sets in the UK Biobank data, which shows that their partitioned abdominal obesity PRSs differ by the risk allele carrier status of the SREBF1 879 880 abdominal obesity GWAS variants, thus highlighting their downstream trans effects of the 881 SREBF1 variants also at the genomic level. Overall, our results identify trans effects on SAT 882 adipocyte gene expression by the WHRadjBMI risk variants in the SREBF1 region using several 883 different data modalities and cohorts. Given the known important TF functional of SREBF1, our 884 results support the notion that these WHRadjBMI GWAS risk variants in the regulatory region of 885 SREBF1 have downstream effects in trans on transcriptional regulation of numerous central 886 obesity -related genes. More broadly, our study also provides an integrative genomics approach, 887 leveraging single cell omics and biobank data, that can be generalized to other TFs to accelerate 888 the currently slow discovery of *trans* effects of TF GWAS variants.

889

890 We acknowledge several limitations in our study. First, while our KOBS snRNA-seq data pass a 891 rigorous QC, the total number of SAT and VAT nuclei in the KOBS cohort are relatively small. 892 However, the publicly available VAT snRNA-seq data are currently very sparse, and using our 893 dual tissue study design with both SAT and VAT biopsies from the same Finnish individuals 894 with obesity, we at least partially circumvent a well known factor in snRNA-seq data analysis, i.e., the interindividual cellular heterogeneity<sup>34,49</sup> that may affect the assessment of the cell-type 895 896 marker genes. Furthermore, we conducted the risk allele carrier status -based analyses in the 897 large independent RYSA snRNA-seq data set and confirmed the key SAT and VAT results of 898 the *SREBF1* cell-type level expression in the RYSA cohort and previous adipose ATLAS by 899 Emont and coworkers<sup>34</sup>. Second, as we assessed adipogenesis data only from the SAT depot due

900	to the well-known practical and technical challenges to obtain viable human VAT primary
901	preadipocytes - which is also reflected by the current lack of longitudinal human VAT
902	adipogenesis RNA-seq data in the public data repositories - it would be important to also explore
903	adipogenesis differentiating human VAT primary preadipocytes in future studies. Third, the
904	cohorts and analyses of this study comprise Europeans from Finland and the UK. Extrapolations
905	to diverse ethnicities are warranted to further investigate these findings. Lastly, the SAT and
906	VAT biopsies in the current study are from individuals with obesity and thus, studies in
907	individuals with normal weight and overweight may provide important additional information
908	regarding the impact of the obese condition on these results.
909	
910	
911	
912	
913	
914	
915	
916	
917	
918	
919	
920	
921	
922	

#### 923 Figure Legends

924 Figure 1

925 Adipose single nucleus RNA-sequence data from the KOBS participants' subcutaneous 926 adipose tissue (SAT) and visceral adipose tissue (VAT) identify distinct sets of tissue-927 specific and shared cell-type marker genes. (a) The study design visualized through cohort 928 usage. The data from the individuals in the KOBS cohort were used to identify cell-type marker 929 gene sets, while the data from the individuals in the RYSA cohort were used to identify *trans* 930 gene sets by the carrier status of the *SREBF1* risk alleles. Lastly, all polygenic risk scores were 931 built using individuals from the UK Biobank. (b-c) The integrated SAT and VAT single nucleus RNA-seq data (n=6,732 nuclei) from 7 KOBS participants are visualized in a Uniform Manifold 932 933 Approximation and Projection (UMAP) and colored by (b) fat depot of origin and (c) cluster 934 cell-type identity, while mapping each cluster to one of the 16 identified cell-types. ASPC 935 indicates adipose stem and progenitor cells; B, B cells; LEC, lymphatic endothelial cells; NK, 936 natural killer cells; SMC, smooth muscle cells; and T, T cells. (d) A volcano plot depicts 937 differential expression (DE) of the unique adipocyte marker genes by tissue. Genes are grouped 938 into marker genes specific to SAT (MGSS), specific to VAT (MGSV), and shared between the 939 SAT and VAT tissues (MGSBT) (see Methods), and then colored by these groups. 940

941 Figure 2

942 Regional polygenic risk scores (PRSs) constructed from the *cis* regional variants of the
943 adipocyte MGSS gene sets show enrichment in variance explained for abdominal obesity in
944 all individuals and females of the UK Biobank. Lollipop plots visualize the predictive
945 performance of each regional PRS relative to the 10,000 PRSs built using the same number of

946randomly selected adipocyte-expressed genes. Each horizontal lollipop represents a separate947regional PRS, broken into three categories on the left (all individuals, females, and males). Dot948size corresponds to the variance explained,  $R^2$ , of each PRS. The vertical dotted line represents949the cutoff for significance (p<sub>perm10,000</sub><0.05).</td>

950

951 Figure 3

952 Functional pathway enrichment analyses of cell- and tissue-type level expression profiles 953 reveal distinctive differences in SAT and VAT pathways and highlight the adipose master 954 transcription factor SREBF1 as the central pathway gene present in 87% of the adipocyte 955 MGSS pathways. (a) The top 10 most significant (FDR<0.05) functional pathways for 956 adipocyte MGSS and MGSV are shown side by side, colored by adipocyte tissue-specific set. P-957 values for each pathway are shown on the x-axis, and each pathway is subsequently ranked by 958 decreasing p-value. The point size of each dot corresponds to the enrichment ratio of the 959 pathway. (b) Circos plots visualize the pathway memberships of the adipocyte MGSS genes that 960 appear in  $\geq 8$  adjpocyte MGSS pathways and connect the genes to their respective pathways. 961 Genes denoted with an asterisk are predicted target genes of *SREBF1*. Each gene is colored by 962 the number of pathways it belongs to. We highlight *SREBF1*, an adipose tissue master TF and a 963 key pathway gene that is present in 20 out of 23 pathways enriched in adipocyte MGSSs. (c) The 964 cell-type level expression of *SREBF1* across both fat depots is shown on the UMAP space, 965 separately for SAT and VAT, and colored by normalized gene expression counts. d) The scaled 966 expression counts over a 14-day adjocyte differentiation experiment of the longitudinally 967 differentially expressed (DE) adipocyte MGSS genes with memberships in multiple enriched 968 pathways are plotted and grouped by their longitudinal expression trajectory clusters.

969

#### 970 Figure 4

- 971 Longitudinal trajectory analysis of open chromatin reveals co-accessible peaks in the *cis*
- 972 region of SREBF1 that harbor WHRadjBMI variants. (a) A regional schematic overview
- 973 shows the proximity to *SREBF1* of 5 co-accessible peaks that exhibit very similar open
- 974 chromatin trajectory patterns. The peaks collectively harbor WHRadjGWAS variants, viewable
- 975 through zoomed in loci of the chromosome. (b) The temporal accessibility patterns of the 5 peaks
- 976 in the SREBF1 are plotted across the 14-day, 6 time-point SAT preadipocyte differentiation
- 977 experiment. (c) The pairwise linkage disequilibrium (LD) (R<sup>2</sup>) in the UK Biobank (n=9,981)
- 978 between the 7 WHRadjBMI GWAS SNPs residing within the co-accessible adipocyte peaks in
- 979 the *SREBF1 cis* region is shown as a HaploView plot, colored by  $R^2$ .

980

981 Figure 5

982 Trans effects of SREBF1 abdominal obesity GWAS SNPs established using single cell level 983 expression data and biobank investigation. (a) Trans effects of abdominal obesity GWAS 984 SNPs in the *SREBF1* region on SAT adipocyte expression of the adipocyte MGSS genes in an 985 allele-specific way is shown using module scores, constructed in the RYSA cohort (n=68) using 986 the average SAT adjocyte expression of the upregulated *trans* genes by the risk allele status of 987 the SREBF1 GWAS SNPs. For the module scores of the downregulated trans genes, see 988 Supplementary Figure 4. The plots represent the module scores calculated for the upregulated 989 *trans* genes by each SNP (or by a SNP representing a tight LD block, see Figure 4c). Thus, the 990 module scores for the LD block of rs12948060, rs4646347, and rs4646346 and the LD block of 991 rs7224725 and rs9944423 are shown using the data for rs12948060 and rs7224725. Each point

992	represents a cell and its average gene expression of the <i>trans</i> genes of interest. (b) The
993	differences between the carriers and non-carriers are also visualized through a two-sided
994	Wilcoxon test and boxplot. (c) The trans gene sets are enriched for variance explained in
995	abdominal obesity. Lollipop plots show the regional PRS results for each trans gene set
996	(constructed in all individuals and females). Entries missing a lollipop did not either have enough
997	SNPs to accurately build a PRS (<5 SNPs) or significantly predict the variance in WHRadjBMI
998	$(p_R^2>0.05)$ after the regional PRS construction. (c) Differences in the magnitude of the regional
999	PRSs between the carriers and non-carriers of the abdominal obesity risk allele for rs4924755
1000	visualized through boxplots. Significance is calculated using a two-sided Wilcoxon test. Plots for
1001	the regional WHRadjBMI PRSs of the trans genes calculated in females and all individuals in
1002	UKB are displayed.
1003	
1004	
1005	
1006	
1007	
1008	
1009	
1010	
1011	
1012	
1013	
1014	
1015	
1016	

#### 1017 Author contributions

- 1018 M. G. S. and P. P. designed the study. M. G. S., A. K., S. H. T. L., K. Z. G., and S. S. D.
- 1019 performed computational analysis and relevant literature comparisons. M. G. S., A. K., S. H. T.
- 1020 L., M. A., and P. P. developed the analytical and statistical approaches. K. M. G. and P. P.
- 1021 generated the ATAC-seq data. U. T. A., S. H. T. L., S. R., K. H. P., M. U. K., and P. P. generated
- 1022 the RNA-seq data. M. A., D. K., and P. P. generated the genotype data. D. K., V. M., H. P., S.
- 1023 H., U. S., T. S., A. J., K. H. P., J. P., and M. U. K. collected the cohort materials. M. G. S., A. K.,
- 1024 S. H. T. L., and P. P. wrote the manuscript, and all authors read, reviewed, and/or edited the
- 1025 manuscript.

1026

#### **1027 Declaration of interests**

- 1028 The authors declare no competing interests.
- 1029

#### 1030 Acknowledgments

- 1031 We would like to thank the participants of the KOBS, RYSA, and Tilkka cohorts, and the UK
- 1032 Biobank. This study was supported by NIH grants R01HL170604 (PP) and R01DK132775 (PP),
- 1033 the Academy of Finland (272376, 266286, 314383, 335443, KHP; 314457 AJ: 338417 SH; and
- 1034 333021, 335973, MUK), Finnish Medical Foundation (KHP, AJ), Finnish Diabetes Research
- 1035 Foundation (SH, KHP), Orion Foundation (SH), Novo Nordisk Foundation (NNF10OC1013354,
- 1036 NNF17OC0027232, NNF20OC0060547, KHP), Paulo Foundation (SH, KHP), Gyllenberg
- 1037 Foundation (KHP), Sigrid Juselius Foundation (KHP, MUK), Paavo Nurmi Foundation (SH),
- 1038 Helsinki University Hospital Research Funds (SH, KHP, AJ) and the University of Helsinki
- 1039 (KHP). This research was partly supported by the European Research Council (ERC) under the

1040	European Union's Horizon 2020 research and innovation program (Grant 802825 to MUK), and
1041	the Finnish Foundation for Cardiovascular Research (MUK). We would like to acknowledge
1042	Single Cell Genomics Core and Biocenter Finland for infrastructure support. This work uses data
1043	provided by patients and collected by the NHS as part of their care and support. This research
1044	was conducted using the UK Biobank Resource under application number 33934.
1045	
1046	Supplemental information
1047	Document S1. Supplementary Table 17, Supplementary Table 18, Supplementary Figure 2,
1048	Supplementary Figure 3, Supplementary Figure 4, Supplementary Figure 5
1049	Supplementary Table 1. Excel file containing additional data, related to Figure 1
1050	Supplementary Table 2. Excel file containing additional data, related to Figure 1
1051	Supplementary Table 3. Excel file containing additional data, related to Figure 2
1052	Supplementary Table 4. Excel file containing additional data, related to Figure 3
1053	Supplementary Table 5. Excel file containing additional data, related to Figure 3
1054	Supplementary Table 6. Excel file containing additional data, related to Figure 3
1055	Supplementary Table 7. Excel file containing additional data, related to Figure 3
1056	Supplementary Table 8. Excel file containing additional data, related to Figure 3
1057	Supplementary Table 9. Excel file containing additional data, related to Figure 3
1058	Supplementary Table 10. Excel file containing additional data, related to Figure 3
1059	Supplementary Table 12. Excel file containing additional data, related to Figure 4
1060	Supplementary Table 13. Excel file containing additional data, related to Figure 5
1061	Supplementary Table 14. Excel file containing additional data, related to Figure 5
1062	Supplementary Table 15. Excel file containing additional data, related to Figure 5

1063	Supplementary	Table 16.	Excel file	containing	additional	data, related	to Figure 5
------	---------------	-----------	------------	------------	------------	---------------	-------------

1064

#### 1065 Data availability statement

- 1066 The data that support the findings in this manuscript are available from the UK Biobank.
- 1067 However, restrictions apply to the availability of these data, which were used in this study under
- 1068 UK Biobank Application number 33934. UK Biobank data are available for bona fide
- 1069 researchers through the application process: <u>https://www.ukbiobank.ac.uk/learn-more-about-uk-</u>
- 1070 <u>biobank/contact-us</u>. The KOBS VAT snRNA-seq will be made available in the NIH Gene
- 1071 Expression Omnibus (GEO) upon acceptance, under accession number GSEXX. The KOBS
- 1072 SAT snRNA-seq data were made previously available in GEO, under accession number
- 1073 GSE269926. The RYSA SAT snRNA-seq data will be made available in GEO under accession
- 1074 number GSE274778. The data from the primary human preadipocyte differentiation experiment
- 1075 were previously made available in GEO, under accession number GSE249195 for the RNA and
- 1076 GSE269926 for the ATAC. The SAT and VAT snRNA-seq data described in Emont et al.<sup>34</sup> can
- 1077 be found in the Single Cell Portal under study number SCP1376.

1078

#### 1079 Code availability

1080 No custom code was used, and all codes used for analyses in this study were unaltered from their1081 publicly available sources, as outlined in the Methods.

- 1083
- 1084
- 1085

1	08	36
---	----	----

#### 1087 References

- Vegiopoulos, A., Rohm, M. & Herzig, S. Adipose tissue: between the extremes. *EMBO J.* 36, 1999–
   2017 (2017).
- 1090 2. Merlotti, C., Ceriani, V., Morabito, A. & Pontiroli, A. E. Subcutaneous fat loss is greater than
- visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical
  review and meta-analysis. *Int. J. Obes. 2005* 41, 672–682 (2017).
- 1093 3. Pellegrinelli, V., Carobbio, S. & Vidal-Puig, A. Adipose tissue plasticity: how fat depots respond
  1094 differently to pathophysiological cues. *Diabetologia* 59, 1075–1088 (2016).
- 1095 4. Bays, H. E. *et al.* Pathogenic potential of adipose tissue and metabolic consequences of adipocyte
- 1096 hypertrophy and increased visceral adiposity. *Expert Rev. Cardiovasc. Ther.* 6, 343–368 (2008).
- 1097 5. Gesta, S., Tseng, Y.-H. & Kahn, C. R. Developmental origin of fat: tracking obesity to its source.
  1098 *Cell* 131, 242–256 (2007).
- 6. Garske, K. M. *et al.* Increased body mass index is linked to systemic inflammation through altered
  chromatin co-accessibility in human preadipocytes. *Nat. Commun.* 14, 4214 (2023).
- 1101 7. Lee, S. H. T. *et al.* Single nucleus RNA-sequencing integrated into risk variant colocalization
- discovers 17 cell-type-specific abdominal obesity genes for metabolic dysfunction-associated
- 1103 steatotic liver disease. *EBioMedicine* 106, 105232 (2024).
- 1104 8. Pan, D. Z. *et al.* Integration of human adipocyte chromosomal interactions with adipose gene
- 1105 expression prioritizes obesity-related genes from GWAS. *Nat. Commun.* 9, 1512 (2018).
- 1106 9. Brotman, S. M. et al. Adipose tissue eQTL meta-analysis reveals the contribution of allelic
- 1107 heterogeneity to gene expression regulation and cardiometabolic traits. *BioRxiv Prepr. Serv. Biol.*
- 1108 2023.10.26.563798 (2023) doi:10.1101/2023.10.26.563798.
- 1109 10. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues.
- 1110 *Science* 369, 1318–1330 (2020).

- 1111 11. Pan, D. Z. *et al.* Identification of TBX15 as an adipose master trans regulator of abdominal obesity
- **1112** genes. *Genome Med.* 13, 123 (2021).
- 1113 12. Grundberg, E. *et al.* Mapping cis- and trans-regulatory effects across multiple tissues in twins. *Nat.*
- 1114 *Genet.* 44, 1084–1089 (2012).
- 1115 13. Civelek, M. et al. Genetic Regulation of Adipose Gene Expression and Cardio-Metabolic Traits. Am.
- 1116 J. Hum. Genet. 100, 428–443 (2017).
- 1117 14. Ayala-Sumuano, J.-T. *et al.* Srebf1a is a key regulator of transcriptional control for adipogenesis. *Sci.*1118 *Rep.* 1, 178 (2011).
- 1119 15. Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent physiology divergent
  pathophysiology. *Nat. Rev. Endocrinol.* 13, 710–730 (2017).
- 1121 16. van der Kolk, B. W. et al. Differential Mitochondrial Gene Expression in Adipose Tissue Following
- 1122 Weight Loss Induced by Diet or Bariatric Surgery. J. Clin. Endocrinol. Metab. 106, 1312–1324
- 1123 (2021).
- 1124 17. Pihlajamäki, J. *et al.* Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after
  gastric banding. *Metabolism.* 59, 866–872 (2010).
- 1126 18. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562,
  1127 203–209 (2018).
- 1128 19. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation. *Nature* 526,
  68–74 (2015).
- 1130 20. Heinonen, S. et al. Roux-en-Y versus one-anastomosis gastric bypass (RYSA study): weight loss,
- 1131 metabolic improvements, and nutrition at 1 year after surgery, a multicenter randomized controlled
- trial. Obes. Silver Spring Md 31, 2909–2923 (2023).
- 1133 21. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets.
  1134 *GigaScience* 4, s13742-015-0047–8 (2015).
- 1135 22. McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48,
- 1136 1279–1283 (2016).

- 1137 23. Loh, P.-R. et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat.
- **1138** *Genet.* 48, 1443–1448 (2016).
- 1139 24. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* 48, 1284–1287
  1140 (2016).
- 1141 25. GENCODE 2021 PubMed. https://pubmed.ncbi.nlm.nih.gov/33270111/.
- 1142 26. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma. Oxf. Engl. 29, 15–21
- 1143 (2013).
- 1144 27. Alvarez, M. et al. Enhancing droplet-based single-nucleus RNA-seq resolution using the semi-
- supervised machine learning classifier DIEM. *Sci. Rep.* 10, 11019 (2020).
- 1146 28. Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573-3587.e29 (2021).
- 1147 29. Yang, S. *et al.* Decontamination of ambient RNA in single-cell RNA-seq with DecontX. *Genome*1148 *Biol.* 21, 57 (2020).
- 30. Kang, H. M. *et al.* Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. *Nat. Biotechnol.* 36, 89–94 (2018).
- 1151 31. McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: Doublet Detection in Single-Cell
- 1152 RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst.* 8, 329-337.e4 (2019).
- 1153 32. Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat.*1154 *Methods* 16, 1289–1296 (2019).
- 33. Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional
  profibrotic macrophage. *Nat. Immunol.* 20, 163–172 (2019).
- 1157 34. Emont, M. P. *et al.* A single-cell atlas of human and mouse white adipose tissue. *Nature* 603, 926–
  1158 933 (2022).
- 1159 35. Zheng, G. X. Y. *et al.* Massively parallel digital transcriptional profiling of single cells. *Nat.*1160 *Commun.* 8, 14049 (2017).
- 1161 36. Tutorial: guidelines for annotating single-cell transcriptomic maps using automated and manual
- 1162 methods | Nature Protocols. https://www.nature.com/articles/s41596-021-00534-0.

- 1163 37. Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: gene set analysis toolkit
  1164 with revamped UIs and APIs. *Nucleic Acids Res.* 47, W199–W205 (2019).
- 1165 38. Segrè, A. V. et al. Common inherited variation in mitochondrial genes is not enriched for
- associations with type 2 diabetes or related glycemic traits. *PLoS Genet.* 6, e1001058 (2010).
- 39. Suzuki, K. *et al.* Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. *Nature* 627,
  347–357 (2024).
- 40. Collister, J. A., Liu, X. & Clifton, L. Calculating Polygenic Risk Scores (PRS) in UK Biobank: A
  Practical Guide for Epidemiologists. *Front. Genet.* 13, 818574 (2022).
- 1171 41. Sw, C., Ts, M. & Pf, O. Tutorial: a guide to performing polygenic risk score analyses. *Nat. Protoc.*1172 15, (2020).
- 1173 42. Fried, S. K., Lee, M.-J. & Karastergiou, K. Shaping fat distribution: new insights into the molecular
- 1174 determinants of depot- and sex-dependent adipose biology. *Obes. Silver Spring Md* 23, 1345–1352
- 1175 (2015).
- 1176 43. Schorr, M. *et al.* Sex differences in body composition and association with cardiometabolic risk. *Biol.*1177 *Sex Differ.* 9, 28 (2018).
- 44. Mak, T. S. H., Porsch, R. M., Choi, S. W., Zhou, X. & Sham, P. C. Polygenic scores via penalized
  regression on summary statistics. *Genet. Epidemiol.* 41, 469–480 (2017).
- 45. Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using high-density
  imputation and islet-specific epigenome maps. *Nat. Genet.* 50, 1505–1513 (2018).
- 46. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat. Genet.* 54,
  573–580 (2022).
- 47. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in
  genome-wide association studies. *Nat. Genet.* 47, 291–295 (2015).
- 1186 48. Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide
- association summary statistics. *Nat. Genet.* 47, 1228–1235 (2015).

- 1188 49. Kar, A. *et al.* Age-dependent genes in adipose stem and precursor cells affect regulation of fat cell
- differentiation and link aging to obesity via cellular and genetic interactions. *Genome Med.* 16, 19
- 1190 (2024).
- 50. Fischer, D. S., Theis, F. J. & Yosef, N. Impulse model-based differential expression analysis of time
  course sequencing data. *Nucleic Acids Res.* 46, e119 (2018).
- 1193 51. McDowell, I. C. *et al.* Clustering gene expression time series data using an infinite Gaussian process
- 1194 mixture model. *PLoS Comput. Biol.* 14, e1005896 (2018).
- 1195 52. Pulit, S. L. et al. Meta-analysis of genome-wide association studies for body fat distribution in
- 1196 694 649 individuals of European ancestry. *Hum. Mol. Genet.* 28, 166–174 (2019).
- 53. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNAseq data with DESeq2. *Genome Biol.* 15, 550 (2014).
- 54. Emdin, C. A. *et al.* Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2
  Diabetes, and Coronary Heart Disease. *JAMA* 317, 626–634 (2017).
- 1201 55. Rask-Andersen, M., Karlsson, T., Ek, W. E. & Johansson, Å. Genome-wide association study of
- body fat distribution identifies adiposity loci and sex-specific genetic effects. *Nat. Commun.* 10, 339
  (2019).
- 1204 56. Vecchié, A. *et al.* Obesity phenotypes and their paradoxical association with cardiovascular diseases.
  1205 *Eur. J. Intern. Med.* 48, 6–17 (2018).
- 1206 57. González, N., Moreno-Villegas, Z., González-Bris, A., Egido, J. & Lorenzo, Ó. Regulation of
- visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and
  diabetes. *Cardiovasc. Diabetol.* 16, 44 (2017).
- 1209 58. Li, L.-Y. et al. Interplay and cooperation between SREBF1 and master transcription factors regulate
- 1210 lipid metabolism and tumor-promoting pathways in squamous cancer. *Nat. Commun.* 12, 43621211 (2021).
- 1212 59. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of
- 1213 cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125–1131 (2002).

- 1214 60. Obradovic, M. et al. Leptin and Obesity: Role and Clinical Implication. Front. Endocrinol. 12,
- **1215** 585887 (2021).
- 1216 61. Matsukawa, T. et al. Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease
- and diabetes in mouse obesity models. *JCI Insight* 8, e161282 (2023).
- 1218 62. Graham, S. E. *et al.* The power of genetic diversity in genome-wide association studies of lipids.
- 1219 *Nature* 600, 675–679 (2021).
- 1220 63. Fox, C. S. *et al.* Abdominal visceral and subcutaneous adipose tissue compartments: association with
  1221 metabolic risk factors in the Framingham Heart Study. *Circulation* 116, 39–48 (2007).
- 1222 64. Gealekman, O. et al. Depot-specific differences and insufficient subcutaneous adipose tissue
- angiogenesis in human obesity. *Circulation* 123, 186–194 (2011).
- 1224 65. Chau, Y.-Y. *et al.* Visceral and subcutaneous fat have different origins and evidence supports a
  1225 mesothelial source. *Nat. Cell Biol.* 16, 367–375 (2014).
- 1226 66. Pou, K. M. et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to
- markers of inflammation and oxidative stress: the Framingham Heart Study. *Circulation* 116, 1234–
  1228 1241 (2007).
- 1229 67. Norreen-Thorsen, M. *et al.* A human adipose tissue cell-type transcriptome atlas. *Cell Rep.* 40,
  1230 111046 (2022).
- 68. Ahn, J., Wu, H. & Lee, K. Integrative Analysis Revealing Human Adipose-Specific Genes and
  Consolidating Obesity Loci. *Sci. Rep.* 9, 3087 (2019).
- 1233 69. Arner, P. Differences in lipolysis between human subcutaneous and omental adipose tissues. *Ann.*1234 *Med.* 27, 435–438 (1995).
- 1235 70. Vijay, J. *et al.* Single-cell analysis of human adipose tissue identifies depot and disease specific cell
  1236 types. *Nat. Metab.* 2, 97–109 (2020).
- 1237 71. Milić, S., Lulić, D. & Štimac, D. Non-alcoholic fatty liver disease and obesity: biochemical,
- 1238 metabolic and clinical presentations. *World J. Gastroenterol.* 20, 9330–9337 (2014).

- 1239 72. Polyzos, S. A., Kountouras, J. & Mantzoros, C. S. Obesity and nonalcoholic fatty liver disease: From
- 1240 pathophysiology to therapeutics. *Metabolism.* 92, 82–97 (2019).
- 1241 73. Zacharia, A. et al. Distinct infrastructure of lipid networks in visceral and subcutaneous adipose
- 1242 tissues in overweight humans. *Am. J. Clin. Nutr.* 112, 979–990 (2020).

1243

**Table 1.** Variants in the *cis* regions of genes in the SAT and tissue-shared adipocyte unique marker gene sets are significantly enriched for obesity and type 2 diabetes GWAS SNPs.

Gene set <sup>A</sup>	GWAS outcome <sup>B</sup>	<b>FDR</b> <sup>C</sup>
Adipocyte MGSS	T2D	$4.30 \times 10^{-3}$
Adipocyte MGSS	WHRadjBMI	$1.77 \times 10^{-2}$
ASPC MGSBT	BMI	$2.93 \times 10^{-2}$

<sup>A</sup>MGSS indicates the unique marker genes specific to subcutaneous adipose tissue (SAT), and MGSBT the unique marker genes shared between the two fat depots.

<sup>B</sup> WHRadjBMI indicates waist-hip-ratio adjusted for body mass index, T2D type 2 diabetes, BMI body mass index, and GWAS genome-wide association study.

<sup>C</sup> Significance was determined by comparing observed vs expected number of genes that passed 75%

enrichment cutoff using MAGENTA<sup>38</sup>.

 Table 2. Open chromatin peaks co-accessible during human SAT adipogenesis in the *cis* region of *SREBF1* 

 harbor seven genome-wide significant WHRadjBMI GWAS variants from GIANT-UKB WHRadjBMI

 GWAS<sup>52</sup>.

Variant Effect Males		ales	Females		All individuals		
variant	allele <sup>A</sup>	Beta <sup>B</sup>	p-value	Beta	p-value	Beta	p-value
rs4924755	G	0.0133	8.32×10 <sup>-6</sup>	0.0209	2.05×10 <sup>-15</sup>	0.0186	6.89×10 <sup>-21</sup>
rs12948060	Т	0.0183	1.60×10 <sup>-11</sup>	3.80×10 <sup>-3</sup>	0.114	9.30×10 <sup>-3</sup>	2.64×10 <sup>-7</sup>
rs35104205	С	0.0199	1.75×10 <sup>-11</sup>	0.0149	2.45×10 <sup>-8</sup>	0.0167	3.56×10 <sup>-17</sup>
rs4646347	Т	0.0199	2.81×10 <sup>-11</sup>	$1.50 \times 10^{-3}$	0.579	8.90×10 <sup>-3</sup>	8.37×10 <sup>-6</sup>
rs4646346	С	0.0199	2.43×10 <sup>-11</sup>	9.00×10 <sup>-4</sup>	0.738	8.60×10 <sup>-3</sup>	1.92×10 <sup>-15</sup>
rs9944423	G	8.50×10 <sup>-3</sup>	0.103	0.0394	1.38×10 <sup>-16</sup>	0.0258	4.27×10 <sup>-13</sup>

<sup>A</sup> Trait-increasing allele indicating the allele of the variant that results in a positive effect on waist-hip-ratio adjusted for body mass index (WHRadjBMI).

<sup>B</sup> Effect size on WHRadjBMI per copy of WHRadjBMI-increasing allele.

Table 3. Investigation of seven WHRadjBMI GWAS variants for histone modifications reveals activity in

enhancer and promoter regions.

Variant	Group <sup>A</sup>	Chromatin states (15-state model) <sup>B</sup>	Chromatin states (25-state model) <sup>C</sup>	H3K4me1 <sup>D</sup>	H3K4me3 <sup>E</sup>	H3K27ac <sup>F</sup>	H3K9ac <sup>G</sup>
	Fat.Msc.Dr.Adip	TssAFlnk	TxReg	Enh	Pro	-	Pro
rs4924755	Fat.Adip.Dr.Msc	TssAFlnk	EnhA1	Enh	Pro		Pro
	Fat.Adip.Nuc	TssAFlnk	TxReg	Enh	Pro	Enh	Pro
	Fat.Msc.Dr.Adip	TssAFlnk	EnhA1	Enh	Pro	-	Pro
rs12948060	Fat.Adip.Dr.Msc	Enh	EnhAF	Enh	-	-	Pro
	Fat.Adip.Nuc	Enh	EnhW2	Enh	Pro	Enh	Pro
	Fat.Msc.Dr.Adip	TssAFlnk	TxReg	Enh	Pro	-	Pro
rs35104205	Fat.Adip.Dr.Msc	Enh	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Nuc	TssAFlnk	EnhA1	Enh	Pro	Enh	Pro
	Fat.Msc.Dr.Adip	TssAFlnk	TxReg	Enh	Pro	-	Pro
rs4646347	Fat.Adip.Dr.Msc	Enh	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Nuc	TssAFlnk	EnhA1	Enh	Pro	Enh	Pro
	Fat.Msc.Dr.Adip	TssAFlnk	TxReg	Enh	Pro	-	Pro
rs4646346	Fat.Adip.Dr.Msc	Enh	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Nuc	TssAFlnk	EnhA1	Enh	Pro	Enh	Pro
	Fat.Msc.Dr.Adip	TssAFlnk	EnhA1	Enh	Pro	-	Pro
rs7224725	Fat.Adip.Dr.Msc	TssAFlnk	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Nuc	Enh	PromD1	Enh	Pro	Enh	Pro
	Fat.Msc.Dr.Adip	Enh	EnhA1	Enh	Pro	-	Pro
rs9944423	Fat.Adip.Dr.Msc	Enh	EnhA1	Enh	Pro	-	Pro
	Fat.Adip.Nuc	Enh	TxReg	Enh	Pro	Enh	Pro

<sup>A</sup>Description of cell-line. Fat.Msc.Dr.Adip refers to Mesenchymal Stem Cell Derived Adipocyte Cultured Cells, Fat.Adip.Dr.Msc refers to Adipose Derived Mesenchymal Stem Cell Cultured Cells and Fat.Adip.Nuc refers to Adipose Nuclei.

<sup>B</sup> Chromatin state from the HaploReg database which uses the 15-state core model. TssAFlnk refers to "Flanking Active TSS" and Enh refers to "Enhancers."

<sup>C</sup>Chromatin state from the HaploReg database which uses the 25-state model using 12 imputed marks. TxReg

refers to "Transcribed and regulatory (Prom/Enh)", EnhA1 refers to "Active Enhancer 1", EnhAF refers to

"Active Enhancer Flank", and PromD1 refers to "Promoter Downstream TSS 1."

- <sup>D</sup> Histone modification annotation of type H3K4me1. Enh refers to Enhancer.
- <sup>E</sup> Histone modification annotation of type H3K4me3. Pro refers to Promoter.

<sup>F</sup> Histone modification annotation of type H3K27ac. Enh refers to Enhancer.

<sup>G</sup> Histone modification annotation of type H3K9ac. Pro refers to Promoter.



UMAP\_1





All				
Fem				
ale				
S				
Z				
lale				
Š				
	3	ξ	5	E







## rs4924755

## rs35104205



